Well this has been a week.
I did blog about having a scan WELL on Tuesday my Doctor phoned to tell me that the Mesothelioma has broken through to my spine at the third Vertebra.
So he said they have had a discussion with my Team and Prof De Bono and they have decided to restart my trial on Monday. Ray cant come in with me I have to do this all on my own for the first time in 11 years.
Ray is my rock so I will miss him and he will sit in the car for a long time on Monday and Tuesday but shorter time on Wednesday Thursday and Friday as its just an injection.
I must admit I have had a bad week as this has shattered my nerves but my groups and Mesowarriors have helped to get back up.
I kept busy by doing 2 Zoomed and webinars everyday so I have studied Law with 12KBW and Been to the US to ADAO to listen to Dr. Jacki Moline and Robert Sussman and their expert insight as they discussed “Asbestos, Talc, Prevention, and Policy” on May 13.
I sat in a great meeting with the great team that run the Confirm Trial which has done so well requiting over 300 patients and now its in the process of presenting to NICE I pray they agree to licence our first Immunotherapy for Mesothelioma.
Then I sat in IOSH’s meeting “Returning to work after Covid-19 – the role of OSH and HR professionals”
So It turned out a good week but the Icing on the cake is The Royal Marsden published my DNA findings on my MSD Trial Mk3475/28
I have given many Bi-Ops and from that they raised some wonderful pictures that Anna Minchom At The Royal Marsden had shown me on her Laptop last year as she was so excited about the paper she was writing.
Dean fennel asked in the confirm meeting if I had seen it, I hadnt so Peter sent the link to me and I was so proud I shared the link with people I knew would be interested. So here it is
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069263/
I wont copy all of it as I would rather people went in and read it for themselves as it is very Scientific but My story is brilliant as it is a true record from my files and makes me realise I havent told the story as well as you mind only remembers what it want to. so here it is
Case presentation
Clinical background
The patient is a 77-year-old Caucasian woman. She was diagnosed with a left epithelioid mesothelioma on video-assisted thorascopic biopsy in 2009 with pleurally based nodules in the left hemothorax on radiologic assessment. She underwent talc pleurodesis and four cycles of cisplatin and pemetrexed. Sixteen months later, she developed progressive disease and was treated on a trial of NGR-hTNF (a selective vascular inhibitor) for 4 months to disease progression. She underwent rechallenge with four cycles of pemetrexed and cisplatin, achieving disease stability for 11 months. She then received six cycles of carboplatin and gemcitabine achieving disease stability for 6 months.
From June 2014 to June 2016, she received 52 cycles of pembrolizumab (MK-3475) at a dose of 10 mg/kg every 2 weeks on a phase Ib clinic trial (KEYNOTE-028). The tumor biopsy fulfilled criteria for PD-L1 positivity as per trial protocol. She tolerated drug well with immune-related adverse events of grade 2 pruritic rash and grade 1 mucositis, remaining ECOG (Eastern Cooperative Oncology Group) performance status 1. A partial response was seen on imaging after 3 months, with a 91% reduction in target lesions, which was maintained until June 2016 (figure 1). In April 2018, 21 months after completing 2 years of pembrolizumab, she developed asymptomatic, small volume, radiologic disease progression and recommenced pembrolizumab on study, per protocol, on the same schedule. Following three cycles, a 12% reduction in tumor size by RECIST (Response evaluation criteria in solid tumour) criteria from the prerechallenge baseline was seen. Stable disease was maintained for 25 cycles when radiologic disease progression was confirmed.
(A) Axial enhanced CT of thorax. Upper left panel a: baseline prior to commencing pembrolizumab trial (June 2014) with left posterior parietal malignant pleural disease (white circle). Upper right panel b: maintained partial response after 52 cycles pembrolizumab (April 2016) with minimal residual pleural thickening (white arrow). Lower left panel c: disease progression (July 2018) at site of previous disease along the left posterior parietal pleura (white circle). Lower right panel d: partial response in left parietal posterior pleural disease following three cycles pembrolizumab rechallenge. (B) Tumor response.
I leave you now to read what you choose to.
from Rayandmave's Blog https://ift.tt/2WxQdWh
via IFTTT
No comments: